AXDX * Stock Overview
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Accelerate Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.60 |
| 52 Week High | US$170.00 |
| 52 Week Low | US$15.00 |
| Beta | 0.53 |
| 1 Month Change | -13.33% |
| 3 Month Change | n/a |
| 1 Year Change | -87.32% |
| 3 Year Change | -99.13% |
| 5 Year Change | n/a |
| Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXDX * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | -2.5% | 0% | 0% |
| 1Y | -87.3% | 0% | 0% |
Return vs Industry: AXDX * underperformed the MX Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: AXDX * underperformed the MX Market which returned 2.7% over the past year.
Price Volatility
| AXDX * volatility | |
|---|---|
| AXDX * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: AXDX * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AXDX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 134 | Jack Phillips | acceleratediagnostics.com |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Accelerate Diagnostics, Inc. Fundamentals Summary
| AXDX * fundamental statistics | |
|---|---|
| Market cap | Mex$342.94m |
| Earnings (TTM) | -Mex$1.05b |
| Revenue (TTM) | Mex$205.23m |
1.7x
P/S Ratio-0.3x
P/E RatioIs AXDX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXDX * income statement (TTM) | |
|---|---|
| Revenue | US$12.06m |
| Cost of Revenue | US$9.51m |
| Gross Profit | US$2.55m |
| Other Expenses | US$64.17m |
| Earnings | -US$61.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 21.15% |
| Net Profit Margin | -510.97% |
| Debt/Equity Ratio | -185.2% |
How did AXDX * perform over the long term?
See historical performance and comparison